Mildronate (Meldonium Dihydrate)

Meldonium inhibits the enzyme γ‑butyrobetaine hydroxylase, reducing the synthesis of carnitine. Lower carnitine levels shift heart muscle metabolism from fatty‑acid oxidation toward glucose oxidation, a pathway that generates more ATP per unit of oxygen. This metabolic shift enhances heart performance during low‑oxygen states.

The dosage of Meldonium is individualized. A qualified prescriber determines the appropriate strength, frequency and duration based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for Meldonium in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Meldonium differs from traditional anti‑ischemic drugs such as nitrates or beta‑blockers by targeting cardiac metabolism rather than vascular tone. While nitrates dilate coronary vessels and beta‑blockers reduce heart rate, Meldonium enhances the efficiency of energy production in heart cells. It may be used alone or in combination with other agents, depending on clinical judgment.

Mildronate tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity. No special refrigeration is required for this oral formulation.

Mildronate is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a glass of water. Patients should not crush, split, or chew the tablets unless specifically instructed by a healthcare professional.

The most serious adverse reactions reported with Meldonium are severe allergic responses (anaphylaxis) and cardiac arrhythmias. Patients experiencing sudden rash, swelling, difficulty breathing, or irregular heartbeats should seek immediate medical attention. Routine monitoring of cardiac rhythm and signs of hypersensitivity is advisable during therapy.

Meldonium is contraindicated in individuals with known hypersensitivity to meldonium or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, uncontrolled hypertension, or those taking monoamine oxidase inhibitors. Pregnant or breastfeeding women should avoid use unless a physician determines that the benefits outweigh the risks.